April 25, 2025 06:38 AM EDT

Merck KGaA closes in on SpringWorks deal at $3.5B price point

Ayisha Sharma

News Reporter

Merck KGaA said Thursday that its late-stage discussions to buy the rare cancer biotech SpringWorks Therapeutics have landed on a likely price of $47 per …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck KGaA closes in on SpringWorks deal at $3.5B price point

Ayisha Sharma

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership

AbbVie's immunology franchise remains a powerhouse, as Skyrizi, Rinvoq combine for $5B

Versant's latest biotech focuses on inflammatory diseases

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Merck KGaA closes in on SpringWorks deal at $3.5B price point